Filing Flows › Atara Biotherapeutics (ATRA) › Q2 2026
Atara Biotherapeutics (ATRA) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 12, 2026
Atara Biotherapeutics (ATRA) reported revenue of $630K for the second quarter 2026 (Q2 2026), -96% from a year earlier and +22% from the quarter before. Operating margin was -749.2%, net loss $4.8M (767.3% of revenue).
Atara Biotherapeutics, Q2 2026: revenue $630K (-96% year over year), operating margin -749.2%, net loss $4.8M, operating cash flow −$3.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $630K | +22% | -96% |
| Operating profit | −$4.7M | — | -248% |
| Net earnings | −$4.8M | — | -303% |
| Operating cash flow | −$3.3M | — | — |
What changed
Revenue was $630K in Q2 2026, down 96% year over year and up 22% from the previous quarter.
Operating costs exceeded revenue by $4.7M, an operating margin of -749.2%. Total costs fell 63% while revenue fell 96%. The quarter ended with a net loss of $4.8M, wider than the previous quarter's $4.1M loss.
Operating cash flow was −$3.3M. Non-cash charges added back $14K of depreciation and amortization and $394K of share-based compensation. Working capital and other items added $1.1M.
Questions
What was Atara Biotherapeutics' revenue in the second quarter 2026?
Atara Biotherapeutics (ATRA) reported revenue of $630K for the second quarter 2026 (Q2 2026), -96% from a year earlier and +22% from the quarter before.
Was Atara Biotherapeutics profitable in the second quarter 2026?
Operating loss was $4.7M (-749.2% of revenue) and net loss $4.8M.